BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – William Blair lowered their FY2018 earnings estimates for BioDelivery Sciences International in a report issued on Tuesday. William Blair analyst T. Lugo now forecasts that the specialty pharmaceutical company will post earnings of ($0.72) per share for the year, down from their previous estimate of ($0.71).

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Monday, May 15th. The specialty pharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.49. The business had revenue of $29.48 million for the quarter, compared to analyst estimates of $27.07 million. BioDelivery Sciences International had a negative net margin of 0.19% and a negative return on equity of 1.45%.

ILLEGAL ACTIVITY NOTICE: “William Blair Brokers Cut Earnings Estimates for BioDelivery Sciences International, Inc. (NASDAQ:BDSI)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/20/william-blair-brokers-cut-earnings-estimates-for-biodelivery-sciences-international-inc-nasdaqbdsi.html.

A number of other equities research analysts have also weighed in on BDSI. Cantor Fitzgerald set a $3.00 target price on shares of BioDelivery Sciences International and gave the company a “hold” rating in a research note on Wednesday, March 22nd. Roth Capital set a $5.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Wednesday, March 22nd. FBR & Co set a $4.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Tuesday, May 16th. ValuEngine raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Friday, May 19th. Finally, HC Wainwright initiated coverage on shares of BioDelivery Sciences International in a research note on Friday, May 26th. They set a “buy” rating and a $4.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. BioDelivery Sciences International currently has a consensus rating of “Hold” and an average price target of $3.86.

BioDelivery Sciences International (NASDAQ:BDSI) traded up 2.3067% during trading on Thursday, reaching $3.0692. 88,866 shares of the company traded hands. The firm’s 50 day moving average price is $2.62 and its 200 day moving average price is $2.09. BioDelivery Sciences International has a 12-month low of $1.50 and a 12-month high of $3.14. The firm’s market capitalization is $169.80 million.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. NEXT Financial Group Inc boosted its position in shares of BioDelivery Sciences International by 9.3% in the second quarter. NEXT Financial Group Inc now owns 47,000 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 4,000 shares during the period. GSA Capital Partners LLP acquired a new position in shares of BioDelivery Sciences International during the fourth quarter worth about $142,000. A.R.T. Advisors LLC boosted its position in shares of BioDelivery Sciences International by 174.8% in the fourth quarter. A.R.T. Advisors LLC now owns 98,100 shares of the specialty pharmaceutical company’s stock worth $171,000 after buying an additional 62,400 shares during the period. KCG Holdings Inc. boosted its position in shares of BioDelivery Sciences International by 469.9% in the first quarter. KCG Holdings Inc. now owns 110,728 shares of the specialty pharmaceutical company’s stock worth $210,000 after buying an additional 91,297 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of BioDelivery Sciences International during the first quarter worth about $290,000. 40.32% of the stock is owned by institutional investors.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.